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The clinical outcomes of primary immunodeficiencies (PIDs) are greatly improved by
accurate diagnosis early in life. However, it is not common to consider PIDs before
the manifestation of severe clinical symptoms. Including PIDs in the nation-wide
newborn screening programs will potentially improve survival and provide better disease
management and preventive care in PID patients. This calls for the detection of
disease biomarkers in blood and the use of dried blood spot samples, which is a part
of routine newborn screening programs worldwide. Here, we developed a newborn
screening method based on multiplex protein profiling for parallel diagnosis of 22 innate
immunodeficiencies affecting the complement system and respiratory burst function in
phagocytosis. The proposed method uses a small fraction of eluted blood from dried
Dezfouli et al. Newborn Screening for Innate Primary Immunodeficiencies
blood spots and is applicable for population-scale performance. The diagnosis method
is validated through a retrospective screening of immunodeficient patient samples. This
diagnostic approach can pave the way for an earlier, more comprehensive and accurate
diagnosis of complement and phagocytic disorders, which ultimately lead to a healthy
and active life for the PID patients.
Keywords: primary immunodeficiency, complement deficiencies, phagocytic disorders, presymptomatic
diagnosis, newborn screening, dried blood spot, protein profiling
INTRODUCTION
Primary immunodeficiencies (PIDs) are a group of inherited
disorders caused by defects in different components of the
immune system. PIDs may be associated with severe clinical
outcomes if left undiagnosed or untreated (1). However, it is
uncommon to consider PIDs before the manifestation of severe
clinical symptoms. Recently, novel newborn screening assays
have been explored to enable early clinical intervention and
disease management, beginning as early as the presymptomatic
stage at birth. Newborn screening programs based on the use
of dried blood spot (DBS) samples have revolutionized public
healthcare by detecting disorders such as phenylketonuria
(PKU) during the first few days of life (2). Further developments
of this strategy introduced mass spectrometry (MS)-based
screening with improved sensitivity, specificity and capacity
(2). Most recently, DNA-based screening methodologies
have been developed to detect severe PIDs with defects in
adaptive immunity (2). PCR-based screening is being applied
for diagnosing a subset of life-threatening PIDs, including
severe combined immunodeficiency (SCID) and X-linked
agammaglobulinemia (XLA), through the measurement of
episomal excision products of lymphocyte receptors in DBS
samples (3). Selected countries have successfully implemented
SCID-screening and several additional countries worldwide are
considering to include it in their national screening programs (2).
Here, we present a newborn screening based on protein
profiling that broadens the diagnosis to cover other severe
forms of PIDs with innate immunity defects. The screening
enables parallel diagnosis of 22 disorders due to defects in
the complement system or phagocytic function prior to the
onset of clinical symptoms. Complement deficiencies represent
1–29% of all PID cases, (4) giving a cumulative prevalence of 1
in 20,000 live births (5), and phagocytic disorders encompass
5–29% of PIDs, occurring at a prevalence of 1 in 250,000 live
births (1, 6). However, due to the lack of comprehensive and
pre-symptomatic diagnosis, the prevalence rate of these PIDs
is markedly underestimated (7). Accurate and early diagnosis
is vital as complement deficiencies and phagocytic disorders
are associated with numerous immunological complications.
Complement deficiencies cause recurrent and persistent
infections in the upper respiratory tract, recurrent pneumococcal
and meningococcal infections, hereditary angioedema (HAE),
autoimmune complications, and renal failure due to atypical
hemolytic uremic syndrome (aHUS) and glomerulonephritis
(GN) (8). Severe congenital neutropenia (SCN) and chronic
granulomatous disease (CGD) are characterized by low
granulocyte counts or defects in the nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase pathway, leading to
conditions such as delayed wound healing, deep organ infections,
and abscess formation. These infections may become severe
or even lethal, and might lead to development of malignancies
or bone marrow failure (6). Early diagnosis of such disorders
allows immediate clinical intervention and prevention of severe
complications. Moreover, in the case of phagocytic diseases, it
might allow for early stem cell transplantation, with a future
prospect of gene therapy.
Currently, complement functional assays, nephelometry,
immunoprecipitation (IP), enzyme-linked immunosorbent assay
(ELISA), complete blood count and flow-cytometric cellular
characterizations are applied for diagnosis of complement and
phagocytic disorders (5). All these methods are low-throughput,
hardly adaptable to population-scale performance, and can
be costly and labor-intensive to test for several disorders in
one sample. Moreover, the small quantity of blood material
in DBS significantly limits the total number of possible tests
on each sample (9). Accordingly, an alternative diagnostic
method that enables multiple parallel tests and requires minimal
sample volume would greatly improve the clinical procedures,
particularly in newborn screening. Considering the disease
mechanisms of complement and phagocytic defects that involve
the absence, or expression/structural alteration of a functional
protein, protein profiling of blood samples could provide a
fundamental diagnostic tool (10). Here, we developed a newborn
screening assay based on suspension bead array technology for
parallel profiling of the main reported disease-associated proteins
in the complement cascade, phagocytosis and respiratory burst
function (8). The method uses a fraction of DBS corresponding
to a sub-microliter volume of blood, and is applicable for
population-scale performance (Figure 1).
METHODS
Blood Samples and Preparation for Protein
Profiling
Thirty-seven anonymized healthy control samples in forms of
dried blood spot (DBS), serum, and whole blood (including
21 newborn samples) were provided by the Karolinska
University Hospital Huddinge (Sweden) for normal range
identification of the targeted proteins (see Antibodies and
Immunoassay Procedure sections). Moreover, 41 DBS and
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FIGURE 1 | Schematic view of the screening procedure. Drops of blood (∼70 µL) are dried on filter paper. Proteins are eluted and labeled from a punched disc, equal
to a 4.5% fraction of one blood drop. After further dilution (1:500 dilution of blood), proteins are captured on the designed antibody-coupled bead array, and signals
are analyzed with fluorescent-based readout. Stars illustrated fluorescent label. Two laser beams are applied for detection of beads (capture antibodies) and
associated fluorescent signal (from labeled target proteins).
matched serum samples (including five original Guthrie cards
from the Newborn Screening Laboratory, Karolinska University
Hospital, Sweden) with defects in one of the proteins C1,
C2, C3, C4, C5, C6, C7, C8, C9, FB, FD, FH, FI, properdin,
or HAX1 were obtained and prepared for retrospective
screening (Table 1). All human samples used in this study
were collected after informed consent and handled under
the approval of the Regional Ethical Review Board (EPN) in
Stockholm, Sweden.
Filter papers (PerkinElmer) for DBS sampling were provided
by the Newborn Screening Laboratory at the Karolinska
University Hospital Solna (Sweden), and were prepared by
applying 70 µL (corresponding to one drop) fresh and intact
whole blood onto the filter paper. Papers were dried at ambient
temperature (25◦C) for 4 h, before desiccated storage at 4◦C
until use. DBS samples were punched in 3.2mm in diameter
discs (corresponding to 4.5% fraction of one blood drop), and
proteins were eluted by submerging the disc in 30 µL sterile
phosphate buffered saline supplemented with Tween 20 (PBS-
T, pH 7.4, 0.1% Tween 20, Medicago-AB) for 3 days, 1 day,
or 2 h at 4◦C. Subsequently, proteins from the DBS eluate
or 3 µL matched whole blood were biotinylated (referred as
protein labeling) by addition of ten times molar excess of
Sulfo-N-Hydroxysuccinimide-polyethyleneglycol biotin (NHS-
PEG4-Biotin, ThermoFisher Scientific, USA) in 30 µL PBS-
T (referred as labeling solution), with incubation for 2 h at
4◦C. Alternatively, a rapid and simultaneous protein elution
and labeling was performed by submerging the DBS disc in 30
µL of labeling solution for 2 h, 30min, or 10min at ambient
temperature. Labeled samples were stored at −20◦C until use.
Immediately before incubation with the suspension bead array,
1 µL of labeled samples were further diluted 50 times in
PBS buffer supplemented with polyvinylpyrrolidone, polyvinyl
alcohol, and casein (Sigma-Aldrich). The diluted samples were
heat-treated at 56◦C for 30min for signal enhancement (10) and
were cooled down to ambient temperature for 10min prior use.
The effect of heat-treatment on heat-labile complement proteins
with no effect on protein profiling were previously described
(10). The final 1:500 dilution of eluted samples from each
disc provides enough volume for 30 tests, which corresponds
to a 0.1 µL volume of crude whole blood applied to each
multiplexed measurement.
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TABLE 1 | Information on the sample cohort used in retrospective screening.





C1 deficiency 1# Sigma-Aldrich, product# 234401
C2 deficiency 8 (five newborns)* (10, 11) Vall d’Hebron University Hospital, Spain
Son Espases University Hospital, Spain
12 Octubre Hospital, Spain
Karolinska University Hospital, Sweden
C3 deficiency 2# (10) Sigma-Aldrich, product# C8788
Karolinska University Hospital, Sweden
C4 deficiency 1# (10) Karolinska University Hospital, Sweden
C5 deficiency 1 (12) Vall d’Hebron University Hospital, Spain
C6 deficiency 2 Sigma-Aldrich, product# C1288
La Paz University Hospital, Spain
C7 deficiency 3 (13) Son Espases University Hospital, Spain
Sahlgrenska University Hospital, Sweden
National Defense Medical College, Japan
C8 deficiency 1# Sigma-Aldrich, product#C1538
C9 deficiency 4 (14) Fukuoka Children’s Hospital, Japan
National Defense Medical College, Japan
FB deficiency 1 (15) Royal Melbourne Hospital, Australia
FD deficiency 3 (16) Sint Antonius Hospital, the Netherlands
FH deficiency 2# (10) Karolinska University Hospital, Sweden
FI deficiency 8 (17, 18)
Vall d’Hebron University Hospital, Spain
Royal Melbourne Hospital, Australia
San Pedro de Alcántara Hospital, Spain
12 Octubre Hospital, Spain
Properdin deficiency 2 Royal Melbourne Hospital, Australia
Central Hospital, Kristianstad, Sweden
SCN (HAX1 deficiency) 2 (19) Tehran University of Medical Sciences, Iran
Total number of patients 41 See above
Healthy Controls 37 (21 newborns) Karolinska University Hospital, Sweden
*Original Guthrie cards from newborn screening program in Sweden.
#Available sample type is serum.
Antibodies and Immunoassay Procedure
Antibodies targeting the proteins and protein fragments C1qA,
C1qB, C1s, C2b, C3, C3a, C4A, C4B, C5, C6, C7, C8A, C8B, C9,
FB, FD, FH, FI, Properdin, CSF3R, p22-phox, gp91-phox, p47-
phox, p67-phox, p40-phox, ELANE, HAX1, human albumin and
human IgG were covalently coupled to carboxylated fluorescent-
color-coded Luminex MagPlex microspheres (Luminex
Corporation) according to a previously established protocol
(20). In brief, 500,000 microspheres (referred to as beads) were
functionalized using N-Hydroxysuccinimide-polyethyleneglycol
(NHS) and 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC) chemical linkers (ThermoFisher-Scientific) according to
the manufacturer’s protocol, and incubated with 1.65 µg of the
antibody or recombinant protein in 100 µL 2-(N-Morpholino)
ethanesulfonic acid (MES) buffer at pH 5.0 (Sigma-Aldrich)
for 2 h at ambient temperature on a microplate shaker (650
rpm). Remaining active groups on the beads were quenched by
an overnight incubation in 50 µL blocking reagent for ELISA
(Roche). Antibody-coupled beads were pooled in suspension to
be used as the suspension bead array in subsequent experiments.
An array of 42 antibodies targeting the 22 proteins and their
corresponding protein fragments was used for protein profiling
(Table S1).
Fifty microliter of labeled, diluted, and heat-treated samples
were applied to the prepared suspension bead array with bead
counts of minimum 30 beads per target per measurement.
After overnight incubation in a sealed plate at ambient
temperature on a microplate shaker (650 rpm), the beads
were washed three times in 100 µL PBS-T. The sandwich
immunoassay was performed as described above, with the
exception of using unlabeled DBS eluate, and addition of an
incubation step with biotinylated secondary antibodies for 1 h
at ambient temperature, followed by three times washes in
100 µL PBS-T (21). Subsequently, the captured biotin-labeled
proteins on beads (or detection antibodies in sandwich format)
were incubated with 50 µL of Streptavidin R-phycoerythrin
conjugate (SAPE, ThermoFisher-Scientific) at the concentration
of 5µg/mL. After three times washes in 100 µL PBS-T and
resuspension in 100 µL PBS-T, fluorescent signal intensities were
measured in parallel for all targets using Luminex LX200 and
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FLEXMAP 3D systems (Luminex Corporation) according to the
manufacturer’s instructions.
Data Analysis
R software version 3.2.3 and R Studio environment version
0.99.902 were applied for statistical analyses and data
visualization (22). The median fluorescence intensities (MFI)
from the beads regarding each protein target per measurement
were used. The signal-to-background ratio was determined
according to the internal negative control (data from beads with
no capture antibody). Data were normalized and fluorescent
signals were adjusted using the “batch effect removal” function
from the R Limma package (23). The statistical cut-off for the
definition of protein defects (PID level) was considered as an
outlier fluorescent intensity under minimum values that deviates
from the 1.5 times interquartile range (IQR) under the first
quartile of corresponding signals for each protein measurement
in all healthy control samples. Values from PID patients
associated with non-targeted proteins were not considered
as healthy values, as no previous clinical data is available for
non-targeted proteins and deficiency in one complement protein
can cause perturbation in the levels of other proteins due
to regulatory, compensation and feedback mechanisms. The
coefficient of variation (CV) was calculated for the assay as
the ratio of the standard deviation to the mean for triplicate
measurements from three different samples, two different sample
material and 43 antibodies.
RESULTS
Initially, we confirmed protein elution from filter paper of
three healthy controls, evaluated the protein measurements, as
well as testing automation and reduction in turnaround time
(Figure S1A–C). The procedure was set to 30min protein elution
and labeling at ambient temperature, followed by an overnight
protein capture on an antibody-coupled bead array, and parallel
fluorescent-based readout for 30 s per sample on the following
day. The median coefficient of variation (CV) of the method was
calculated to be 15. An optimal limit for blood dilution of above
1:800 was preferred to allow the detection of as many proteins
as possible.
Subsequently, screening was performed on a sample cohort,
including 37 healthy controls and 41 cases diagnosed with PID
(Table 1). The cohort included 26 newborn samples, including
five PID cases of original Guthrie cards from the Newborn
Screening Laboratory at Karolinska Hospital (Sweden) and 21
healthy DBS samples provided by the National Cord Blood
Biobank at Karolinska University Hospital Huddinge (Sweden).
Additionally, these five original Guthrie card samples from
newborns with PID were compared with healthy DBS samples
for confirmation of the newborn screening concept.
Samples were profiled for complement components C1-C9,
complement factors FB, FD, FH, FI, and properdin, as well as
the proteins related to phagocytosis and granulocyte function,
including colony-stimulating factor 3 receptor (CSF3R),
phagocytic oxidase subunits p22-phox, gp91-phox, p47-
phox, p67-phox, and p40-phox, neutrophil elastase (ELANE)
and HCLS1 associated protein X-1 (HAX1) (Table S1). The
deficiency level for each protein was defined based on the
population of 37 healthy samples, as those with a deviation
from healthy control values within the interquartile range of 1.5
(IQR ≥ 1.5). Data obtained from the retrospective screening
confirmed the documented disorders within the analyzed cohort
(Figure 2, Figure S2), mainly in DBS samples collected from
neonates with PID, compared to normal newborn samples or
healthy adults (Table 1). Furthermore, the signals obtained from
deficient samples were shown to be regained by supplementing
the corresponding recombinant protein into the DBS samples
collected from the respective deficient donors (Figure S1D).
The second-tier screening was also shown to be accessible in the
form of sandwich immunoassays, allowing for a more selective
detection of the target proteins (Figure S3). Lastly, the screening
data were further validated by current standard clinical tests in
matched serum samples of the PID cohort (Table S2).
DISCUSSION
Newborn screening programs are required to meet a panel of
defined criteria for the principles and practice of each diagnostic
method to be considered at a public health measure. The main
criteria are that the disorder needs to be a serious health issue
and late-stage treatment would cause increased morbidity and
mortality, while early diagnosis would lead to a significantly
better outcome, a treatment or effective preventive care should be
readily available for the diagnosed condition, the disorder should
have a high enough incidence among the target population, the
costs involved should be economically balanced to adapt for
massive population screening, and the turnaround time from
sampling to data should not exceed 48 h (2).
The genetic disorders of the innate immunity are very serious,
particularly when considering life-threatening infections and
angioedema. Late diagnosis would cause significantly higher
morbidity leading to permanent damage to vital organs and even
death. A strict preventive care such as prophylactic antibody
therapy, preventive treatment for systemic lupus erythematosus
(SLE) and HAE, as well as postponing BCG vaccination and
early hematopoietic stem cell transplantation (HSCT) in CGD
patients would significantly reduce morbidity and mortality.
Currently, the cumulative prevalence of deficiencies of the innate
immunity, which could be markedly underestimated due to lack
of accurate diagnosis, is within the range for newborn screening
(1 in <20,000 live births in the target population). The cost per
assay for the proposed method is below 5 USD for the detection
of the 22 disorders (including the costs for all reagents and
laboratory consumables) and is shown to be in the range of
newborn screening guidelines for massive population screening.
The turnaround time from sampling to data is fewer than 10 h
and fits well with the time standard.
A key benefit of the developed screening system is the notable
number of PID-associated proteins that can be examined in
parallel using a limited amount of sample material. Moreover,
the flexible design of the bead array content enables an optimal
adaptation to national programs of different countries, since
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FIGURE 2 | Data from retrospective PID screening. Protein profiling is done in parallel in a multiplexed measurement and obtained values are shown in separate
boxplots for different disorders from 37 healthy control samples including 21 newborn dried blood spots. The deficiency level (IQR ≥ 1.5) is shown as a red baseline.
Deficient samples (n = 41) are shown in colored asterisks, including five newborn dried blood spots of original Guthrie cards from newborn screening program in
Sweden. SCN stands for severe congenital neutropenia.
the prevalence and mechanism of PIDs are markedly different
among ethnic groups. Nevertheless, the presented screening
might miss identifying cases of rare, newly discovered types of
PIDs, or disorders caused by a dysfunctional protein expression.
Updating the array to include particular antibodies that bind the
mutated, truncated, or distorted protein fragments might further
identify these additional PID cases. The bead array technology
can increase the sample throughput up to 384 individuals per
instrument run, with a readout capacity of up to over 500 proteins
in parallel (10, 20).We have shown the possibility for an extended
array design to reach beyond the presented 22 disorders, by
profiling over 1,000 protein targets in DBS samples (Figure S4).
Taken together, combining the long-established routines
for DBS neonatal sampling with the inherent potential of
multiplexed technologies offers an appealing avenue that can be
readily expanded to nationwide newborn screening for a broader
range of PIDs. In the future perspective, a pilot program would
address the aspects of population-scale screening prior to the
decision of implementation in the national screening programs.
In addition, the actual prevalence rates of these PIDs will be
adjusted based on data from the pilot program. As an instance,
the prevalence of severe combined immunodeficiency (SCID)
in the US was significantly adjusted from 1 in 100,000 to 1 in
58,000 live births before and after the pilot newborn screening
study (24). Although newborn screening of severe diseases like
CGD is urgently required, the pilot screening will confirm the
usefulness of the screening for each country and will support
the governmental decisions on the set of other innate PIDs to
include in the nation-wide screening program. Since our current
suggested method is flexible, depending on the prevalence of
PIDs in a specific country the cost-effectiveness assessments in
their health-care systems can be performed to designed required
custom array. It is estimated that the innate immunodeficiency
screening would benefit 20 newborns per year in Sweden and
6,500 newborns worldwide.
The current study should be considered a “proof of principle”
and the precursor for a pilot study with enough samples
size to make a decision as to cost/benefit and feasibility.
Importantly, the presented approach could pave the way for
an earlier, more comprehensive and accurate diagnosis of
complement and phagocytic disorders. Correct and precise
diagnosis with an insight over several conditions could inform
a better understanding of these diseases by finding patients with
specific or combination of deficiencies, in addition to showing
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the differences between non-functional vs. abrogated protein
expressions.With amore personalized diagnosis at hand, insights
from multi-parameter assays can contribute to a more effective
treatment and preventive care, which ultimately leads to a healthy
and active life for PID patients.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation, to any
qualified researcher.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by the Regional Ethical Review Board (EPN) in
Stockholm, Sweden. Written informed consent to participate in
this study was provided by the participants’ legal guardian/next
of kin.
AUTHOR CONTRIBUTIONS
MD, SB, LS, HA, MN, JS, PN, and LH conceived and designed
the study. MD and SB planned and performed the laboratory
experiments and acquisition of data in screening. LS designed
and performed the validation.MD, SB, LS, HA,MT-R, JS, PN, and
LH analyzed and interpreted the data and revised the manuscript
critically. LS, HA, CF, JF, CS, AR, LF, ML-T, LG-G, LA-M,
YM, YY, VF, ÅL, AA, NR, AM-N, MH-G, UD, LT, TH, SN,
JS, and PN contributed with patient diagnosis and/or providing
of reagents, materials, analysis tools. MD wrote the paper. All
authors approved the final manuscript for submission.
FUNDING
This work was supported by the Swedish Research Council
(VR) and grants provided by the Stockholm County
Council (ALF).
ACKNOWLEDGMENTS
We thank all the donors and their guardians for their willingness
to support this work. We also thank everyone at the Division
of Affinity Proteomics and the Plasma Profiling facility at
SciLifeLab. We acknowledge Dr. Jezabel Varadé, Prof. Ingrid
Winship, Dr. Vanessa Bryant, and Dr. Heleen van Velzen-Blad
for facilitating the arrangements in preparing the sample cohort.
We would like to express our gratitude to Prof. Drik Roos for
support on sample collection, critical reading of the manuscript
and providing helpful comments.
SUPPLEMENTARY MATERIAL




1. Skattum L, van Deuren M, van der Poll T, Truedsson L. Complement
deficiency states and associated infections. Mol Immunol. (2011) 48:1643–55.
doi: 10.1016/j.molimm.2011.05.001
2. King JR, Hammarstrom L. Newborn screening for primary immunodeficiency
diseases: history, current and future practice. J Clin Immunol. (2018) 38:56–66.
doi: 10.1007/s10875-017-0455-x
3. Borte S, von Döbeln U, Fasth A, Wang N, Janzi M, Winiarski J, et
al. Neonatal screening for severe primary immunodeficiency diseases
using high-throughput triplex real-time PCR. Blood. (2012) 119:2552–5.
doi: 10.1182/blood-2011-08-371021
4. Rezaei N, Notarangelo LD, Aghamohammadi A. Primary Immunodeficiency
Diseases. Berlin: Springer (2008).
5. Sjoholm AG, Jonsson G, Braconier JH, Sturfelt G, Truedsson L. Complement
deficiency and disease: an update. Mol Immunol. (2006) 43:78–85.
doi: 10.1016/j.molimm.2005.06.025
6. Lim MS, Elenitoba-Johnson KS. The molecular pathology of primary
immunodeficiencies. J Mol Diagn. (2004) 6:59–83. doi: 10.1016/S1525-
1578(10)60493-X
7. Grumach AS, Kirschfink M. Are complement deficiencies really rare?
Overview on prevalence, clinical importance and modern diagnostic
approach.Mol Immunol. (2014) 61:110–7. doi: 10.1016/j.molimm.2014.06.030
8. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C,
Etzioni A, et al. Human inborn errors of immunity: 2019 update on the
classification from the international union of immunological societies expert
committee. J Clin Immunol. (2020). doi: 10.1007/s10875-019-00737-x. [Epub
ahead of print].
9. Ignjatovic V, Pitt J, Monagle P, Craig JM. The utility of dried blood spots for
proteomic studies: looking forward to looking back. ProteomClin Appl. (2014)
8:896–900. doi: 10.1002/prca.201400042
10. Hamsten C, Skattum L, Truedsson L, von Dobeln U, Uhlen M, Schwenk
JM, et al. Heat differentiated complement factor profiling. J Proteom. (2015)
126:155–62. doi: 10.1016/j.jprot.2015.05.027
11. Turley AJ, Gathmann B, Bangs C, Bradbury M, Seneviratne S, Gonzalez-
Granado LI, et al. Spectrum. and. management. of. complement.
immunodeficiencies. (excluding hereditary angioedema) across Europe.
J Clin Immunol. (2015) 35:199–205. doi: 10.1007/s10875-015-0137-5
12. Colobran R, Franco-Jarava C, Martin-Nalda A, Baena N, Gabau E, Padilla N,
et al. Novel mutations causing C5 deficiency in three North-African Families.
J Clin Immunol. (2016) 36:388–96. doi: 10.1007/s10875-016-0275-4
13. Horiuchi T, Ferrer JM, Serra P, Matamoros N, Lopez-Trascasa M, Hashimura
C, et al. A novel nonsense mutation at Glu-631 in a Spanish family
with complement component 7 deficiency. J Hum Genet. (1999) 44:215–8.
doi: 10.1007/s100380050146
14. Nagata M, Hara T, Aoki T, Mizuno Y, Akeda H, Inaba S, et al.
Inherited deficiency of ninth component of complement: an increased
risk of meningococcal meningitis. J Pediatr. (1989) 114:260–4.
doi: 10.1016/S0022-3476(89)80793-0
15. Slade C, Bosco J, Unglik G, Bleasel K, Nagel M, Winship I.
Deficiency in complement factor B. N Engl J Med. (2013) 369:1667–9.
doi: 10.1056/NEJMc1306326
16. BiesmaDH,HannemaAJ, van Velzen-BladH,Mulder L, van Zwieten R, Kluijt
I, et al. A family with complement factor D deficiency. J Clin Invest. (2001)
108:233–40. doi: 10.1172/JCI200112023
17. Alba-Dominguez M, Lopez-Lera A, Garrido S, Nozal P, Gonzalez-Granado I,
Melero J, et al. Complement factor I deficiency: a not so rare immune defect:
characterization of new mutations and the first large gene deletion. Orphanet
J Rare Dis. (2012) 7:42. doi: 10.1186/1750-1172-7-42
18. Franco-Jarava C, Colobran R, Mestre-Torres J, Vargas V, Pujol-Borrell
R, Hernandez-Gonzalez M. Clinical laboratory standard capillary protein
electrophoresis alerted of a low C3 state and lead to the identification of a
Frontiers in Immunology | www.frontiersin.org 7 March 2020 | Volume 11 | Article 455
Dezfouli et al. Newborn Screening for Innate Primary Immunodeficiencies
Factor I deficiency due to a novel homozygousmutation. Immunol Lett. (2016)
174:19–22. doi: 10.1016/j.imlet.2016.04.011
19. Klein C, Grudzien M, Appaswamy G, Germeshausen M, Sandrock I,
Schaffer AA, et al. HAX1. deficiency. causes. autosomal. recessive. severe.
congenital. neutropenia. (Kostmann disease). Nat Genet. (2007) 39:86–92.
doi: 10.1038/ng1940
20. Schwenk JM, Gry M, Rimini R, Uhlén M, Nilsson P. Antibody suspension
bead arrays within serum proteomics. J Proteome Res. (2008) 7:3168–79.
doi: 10.1021/pr700890b
21. Dezfouli M, Vickovic S, Iglesias MJ, Nilsson P, Schwenk JM,
Ahmadian A. Magnetic bead assisted labeling of antibodies at
nanogram scale. Proteomics. (2014) 14:14–8. doi: 10.1002/pmic.2013
00283
22. R Core Team. R: A Language and Environment for Statistical Computing.
R Foundation for Statistical Computing, Vienna (2013). Available online at:
http://www.R-project.org/
23. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al.
Limma powers differential expression analyses for RNA-sequencing and
microarray studies. Nucleic Acids Res. (2015) 43:e47. doi: 10.1093/nar/
gkv007
24. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott
JK, et al. Newborn screening for severe combined immunodeficiency in
11 screening programs in the United States. JAMA. (2014) 312:729–38.
doi: 10.1001/jama.2014.9133
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Dezfouli, Bergström, Skattum, Abolhassani, Neiman,
Torabi-Rahvar, Franco Jarava, Martin-Nalda, Ferrer Balaguer, Slade, Roos,
Fernandez Pereira, López-Trascasa, Gonzalez-Granado, Allende-Martinez, Mizuno,
Yoshida, Friman, Lundgren, Aghamohammadi, Rezaei, Hernández-Gonzalez,
von Döbeln, Truedsson, Hara, Nonoyama, Schwenk, Nilsson and Hammarström.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Immunology | www.frontiersin.org 8 March 2020 | Volume 11 | Article 455
